CN100409899C - Application of pachyman as disintegrating agent in preparation of medicinal tablet - Google Patents

Application of pachyman as disintegrating agent in preparation of medicinal tablet Download PDF

Info

Publication number
CN100409899C
CN100409899C CNB2006100181464A CN200610018146A CN100409899C CN 100409899 C CN100409899 C CN 100409899C CN B2006100181464 A CNB2006100181464 A CN B2006100181464A CN 200610018146 A CN200610018146 A CN 200610018146A CN 100409899 C CN100409899 C CN 100409899C
Authority
CN
China
Prior art keywords
pachyman
disintegrating agent
tablets
tablet
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2006100181464A
Other languages
Chinese (zh)
Other versions
CN1840197A (en
Inventor
胡先明
张郦
肖玉玲
梁淑彩
邱国福
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuhan University WHU
Original Assignee
Wuhan University WHU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuhan University WHU filed Critical Wuhan University WHU
Priority to CNB2006100181464A priority Critical patent/CN100409899C/en
Publication of CN1840197A publication Critical patent/CN1840197A/en
Application granted granted Critical
Publication of CN100409899C publication Critical patent/CN100409899C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The present invention relates to an application of pachyman as a medicinal disintegrating agent in a process for preparing pharmaceutical tablets. The pachyman provided by the present invention is a good disintegrating agent with high efficiency and has the advantage of good fluidity; the basic requirements for producing the tablets are satisfied; in addition, the water absorption of the pachyman is strong; the bulk density and the expandability are superior; the tablets are evenly distributed in a powdery shape in the disintegration process so that the disintegration performance of the tablets is increased, and the disintegration efficiency of the tablets is increased; the pachyman not only can be used by mixing other disintegrating agents, but also can be used solely as the disintegrating agent with high efficiency; the tablets can be disintegrated in about 3 minutes by the pachyman.

Description

Pachyman is as the application of disintegrating agent in the preparation medicinal tablet
Technical field:
The present invention relates to pachyman as the application of pharmaceutic adjuvant especially disintegrating agent in the preparation medicinal tablet.
Background technology:
Pharmaceutic adjuvant is the material base that pharmaceutical preparation exists, and is the indispensable material of production pharmaceutical preparation, so countries in the world all take much count of the exploitation new type medicinal stuff.
Tablet is a kind of most popular oral solid formulation, improve the quality of tablet, and the adjuvant of selecting for use is a key.Filler and disintegrating agent are topmost adjuvants in the conventional tablet, and the selection of these adjuvants directly influences the inherent quality of tablet and the curative effect of medicine.Adjuvant commonly used at present mainly contains starch based, cellulose family, Sargassum acids, potter's clay class, PVP class, gummy class etc.
Along with the direction of pharmaceutical preparation towards " triple effect " (efficient, quick-acting, long-acting) and " three is little " (toxicity is little, side effect is little, dosage little) develops, make new adjuvant, especially the exploitation that has the natural pharmaceutic adjuvant of good slow release, controlled-release function has more meaning, wherein noticeable especially to the developmental research of natural macromolecule amylose, have a extensive future.
Poria is the dry sclerotia of Polyporaceae plant Poria poria cocos (Schw.) Wolf.Its structure is that a kind of main chain is the glucosan that linear β (1 → 3) glycosidic bond connects, and side chain is connected by β (1 → 6) glycosidic bond by 9~10 outer glucose residues, has the macromolecule polysaccharide structure of similar starch.Poria is a kind of traditional Chinese medicine, and many scholars have carried out extensive studies to it, but experimental results demonstrate, pachyman is as its pharmacological action of medicines such as antitumor and not obvious.Therefore, attempt pachyman is developed as a kind of natural polymer adjuvant, have very big feasibility, novelty and wide application prospect.
Summary of the invention:
The object of the invention is to provide pachyman as the application of disintegrating agent in the preparation medicinal tablet, and pachyman is Powdered homodisperse as the disintegrating agent of tablet in disintegrating procedue, can increase the disintegrate ability of tablet, improves the disintegrate efficient of tablet.
Technical scheme provided by the invention is: pachyman is as the application of disintegrating agent in the preparation medicinal tablet.
Above-mentioned pachyman can make by the following method, poria cocos sclerotium is worn into 60-200 order powder, be dissolved in the sodium hydroxide or potassium hydroxide solution of 0.5-5wt%, temperature is controlled at 0 ℃~5 ℃, is stirred to thick shape, placed 10-20 hour, sucking filtration, neutralization filtrate leaves standstill, sucking filtration, drying obtains pachyman.
Described pachyman is that structure is to be main chain with β (1 → 3) glycosidic bond, and β (1 → 6) glycosidic bond is the macromolecule polysaccharide of the Polyporaceae plant Poria of side chain, and its preparation method is a sig water lixiviate poria cocos sclerotium powder.Referring to Zhou Yanxia, Tang Minglin, Yin Huian, An Lianying, the extraction of polysaccharide and assay in the Poria, research and development of natural products, 2003, Vol115, Nol4.
The present invention studies its application performance by the investigation to the different aspect of pachyman:
1. investigate the swellability of pachyman.
2. pass through the fixedly flowability of conical bottom method investigation pachyman.
3. investigate the bulk density of pachyman by fixed mount freely falling body method.
4. pachyman is applied to the disintegrating agent of the blank tablet of calcium sulfate, investigates its disintegration properties.
Pachyman can be used for wet granulation in tablet, also can add in the dried granule.Can take outer addition method to the slice, thin piece that hydrophobic drug disintegrate difficulty is bigger; Take interior addition method for the slice, thin piece of easy-formation not; Slice, thin piece for bad disintegrate and don't easy-formation adopts the inside and outside method that both take into account to add.
Above-mentioned experimentation shows that pachyman of the present invention is good efficient disintegrating agent.The pachyman good fluidity can satisfy the fundamental need of tablet manufacturing.In addition, the pachyman water absorption is strong, and has higher bulk density and dilatancy, is Powdered homodisperse in disintegrating procedue, has increased the disintegrate ability of tablet, has improved the disintegrate efficient of tablet.
The specific embodiment:
The following example will further specify the present invention.
Example one: the preparation of pachyman
Commercially available fresh poria cocos sclerotium is clayed into power, cross 60 mesh sieves, get in the NaOH solution that 600g is dissolved in 0.5wt% (the consumption mass ratio of Indian Bread and NaOH solution is 1: 100), temperature is controlled at 0 ℃~5 ℃, be stirred to thick shape, placement is spent the night, and sucking filtration obtains filtrate, use 10% acetic acid neutralization filtrate afterwards, 0 ℃~5 ℃ placements are spent the night, and sucking filtration obtains white precipitate, successively water, ethanol, the washing precipitation of acetone ether, 20 ℃~50 ℃ dryings promptly obtain pachyman.
Example two: the preparation of pachyman
Commercially available fresh poria cocos sclerotium is worn into the powder art, cross 200 mesh sieves, get in the KOH solution that 600g is dissolved in 5wt% (the consumption mass ratio of Indian Bread and NaOH solution is 1: 200), temperature is controlled at 0 ℃~5 ℃, be stirred to thick shape, placement is spent the night, and sucking filtration obtains filtrate, use 10% acetic acid neutralization filtrate afterwards, 0 ℃~5 ℃ placements are spent the night, and sucking filtration obtains white precipitate, successively water, ethanol, the washing precipitation of acetone ether, 20 ℃~50 ℃ dryings promptly obtain pachyman.
The research of pachyman swellability
The research of pachyman swellability
The inventor joins pachyman sample 1g in the 50ml graduated cylinder, adding distil water 50ml, high vibration is suspended in the water powder fully, at interval behind the 10min repetitive vibrations once, leave standstill 48h after, remove supernatant, measure the volume of suction back sample.Characterize the swellability of pachyman with the 1g sample back volume data (5 identical empirical average values) that fully absorbs water.Measurement result sees Table 1.
The comparison of several disintegrating agent flowabilities of table 1
The sample name Suction back volume (mL)
PVPP 7.5
CMS-Na 19.5
L-HPC 9.5
Starch Do not have significantly and expand
Pachyman 43.0
The research of pachyman flowability
The inventor adopts fixedly conical bottom method, and the diameter 3.5cm of bottom, hopper outlet diameter are 1.3cm, outlet pipe range 5.8cm, and the height of pipe end and bottom is 4.5cm.Flowability to several different disintegrating agents is contrasted, and measurement result sees Table 2.
The comparison of several disintegrating agent flowabilities of table 2
The sample name Angle of repose (degree)
PVPP 29.7
CMS-Na 34.6
L-HPC 61.7
Starch 50.8
Pachyman 31.0
The research of the bulk density of pachyman
The inventor adopts the graduated cylinder of 100ml, and each sample is all got 30g, and height of drop is 15.1cm, shakes 5 times by the freely falling body mode and measure in fixed mount, does relatively.(data are 3 times meansigma methods)
The comparison of several disintegrating agent bulk densitys of table 2
The sample name Volume (ml) 3 Bulk density (g/ml)
PVPP 83.0 0.36
CMS-Na 53.3 0.56
L-HPC 68.1 0.44
Starch 53.0 0.57
Pachyman 60.0 0.50
Pachyman is to the research of blank tablet disintegration properties
The inventor adopts calcium sulfate to prepare blank model sheet.The consumption of disintegrating agent is 5%, with the method for disintegrating agent and equivalent 10%PVP slurry moist granulation, adds 0.5% magnesium stearate in the employing, is pressed into the plain sheet of diameter 10mm with single punch tablet machine.Several different disintegrating agents are contrasted, and measurement result sees Table 3.
The comparison of several disintegrating agent disintegration times of table 3
Disintegrating agent Hardness (kg) Disintegration time (s ± SD)
The calcium sulfate blank 4.50 >1800
PVPP 4.49 193±34.5
CMS-Na 4.06 155±19.9
L-HPC 5.96 393±22.8
Starch 5.01 444±56.7
Pachyman 4.73 153±35.6
Above data show, the pachyman good fluidity can satisfy the fundamental need of tablet manufacturing.In addition, the pachyman water absorption is strong, and has higher bulk density and dilatancy, is Powdered homodisperse in disintegrating procedue, has increased the disintegrate ability of tablet, has improved the disintegrate efficient of tablet; Not only can mix and use, also can be used alone as efficient disintegrating agent, and can make tablet disintegrate about 3 minutes with other disintegrating agent.

Claims (2)

1. pachyman is as the application of disintegrating agent in the preparation medicinal tablet.
2. application according to claim 1, it is characterized in that: described pachyman makes by the following method, and poria cocos sclerotium is worn into 60-200 order powder, is dissolved in the sodium hydroxide or potassium hydroxide solution of 0.5-5wt%, temperature is controlled at 0 ℃~5 ℃, be stirred to thick shape, placed sucking filtration 10-20 hour, neutralization filtrate, leave standstill, sucking filtration, drying obtains pachyman.
CNB2006100181464A 2006-01-12 2006-01-12 Application of pachyman as disintegrating agent in preparation of medicinal tablet Expired - Fee Related CN100409899C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2006100181464A CN100409899C (en) 2006-01-12 2006-01-12 Application of pachyman as disintegrating agent in preparation of medicinal tablet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2006100181464A CN100409899C (en) 2006-01-12 2006-01-12 Application of pachyman as disintegrating agent in preparation of medicinal tablet

Publications (2)

Publication Number Publication Date
CN1840197A CN1840197A (en) 2006-10-04
CN100409899C true CN100409899C (en) 2008-08-13

Family

ID=37029497

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2006100181464A Expired - Fee Related CN100409899C (en) 2006-01-12 2006-01-12 Application of pachyman as disintegrating agent in preparation of medicinal tablet

Country Status (1)

Country Link
CN (1) CN100409899C (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103720696B (en) * 2013-12-27 2016-03-30 辰欣药业股份有限公司 A kind of preparation technology improving valsartan and Hydrochlorothiade capsule bioavailability
CN106188324B (en) * 2016-07-13 2018-11-23 武汉大学 Hydroxyethyl pachyman preparation and its as sustained release tablets framework material application
CN107625852B (en) * 2017-09-10 2021-02-02 江西心正药业有限责任公司 Traditional Chinese medicine composition for clearing heat, promoting diuresis, removing blood stasis and stopping leukorrhagia as well as preparation process and application thereof
CN107625925B (en) * 2017-09-10 2020-11-17 江西心正药业有限责任公司 Traditional Chinese medicine composition capable of dispelling wind, relieving exterior syndrome, invigorating stomach and promoting digestion and preparation process and application thereof
CN108113968A (en) * 2018-01-31 2018-06-05 常州康普药业有限公司 A kind of Cimitidine Tablets and preparation method thereof
CN115521386A (en) * 2022-08-18 2022-12-27 安徽中医药大学 Novel pharmaceutic adjuvant pachyman alkaline solution polysaccharide and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1686561A (en) * 2005-04-08 2005-10-26 武汉大学 Modified natural polymer medical adjuvant, its preparation method and use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1686561A (en) * 2005-04-08 2005-10-26 武汉大学 Modified natural polymer medical adjuvant, its preparation method and use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
羧甲基多糖制备及其应用. 伍焜贤等.现代化工,第21卷第2期. 2001
羧甲基多糖制备及其应用. 伍焜贤等.现代化工,第21卷第2期. 2001 *
茯苓中多糖的提取及含量测定. 周燕霞等.天然产物研究与开发,第15卷第4期. 2003
茯苓中多糖的提取及含量测定. 周燕霞等.天然产物研究与开发,第15卷第4期. 2003 *
药用崩解剂性能比较及应用. 沈慧凤等.中国医药工业杂志,第28卷第12期. 1997
药用崩解剂性能比较及应用. 沈慧凤等.中国医药工业杂志,第28卷第12期. 1997 *

Also Published As

Publication number Publication date
CN1840197A (en) 2006-10-04

Similar Documents

Publication Publication Date Title
CN100409899C (en) Application of pachyman as disintegrating agent in preparation of medicinal tablet
JP5788056B2 (en) Wet granulation tableting method using low-substituted hydroxypropylcellulose aqueous dispersion
CN101406294B (en) Dietary fiber and method of preparing dispersible tablet
JP5031054B2 (en) Low substituted hydroxypropyl cellulose and solid preparation containing the same
RU2010101797A (en) PHARMACEUTICAL SOLID PRODUCT CONTAINING BENZAZEPINE AND METHOD FOR PRODUCING IT
EP1903059A3 (en) Low-substituted hydroxypropylcellulose powder and method for producing the same
CN103099793A (en) Tablet and preparation method
CN101053574A (en) Medicinal composition containing chitoser ester and preparation method and application thereof
CN103705536A (en) Pharmaceutical formula of polyhexamethylene guanidine hydrochloride (PHMG) and preparation method
CN100379763C (en) Cross-linked pachyman, its prepn. and uses
CN100502950C (en) Modified natural polymer medical adjuvant, its preparation method and use
KR20020025028A (en) Base Material for Dry Tableting Comprising Low-substituted Hydroxypropyl Cellulose
CN106822097B (en) Orlistat-containing pharmaceutical composition for losing weight
JPS648605B2 (en)
CN101703448A (en) Direct compression process for cefuroxime axetil dispersible tablets
Olorunsola et al. Extraction and physicochemical characterization of a potential multifunctional pharma-excipient from crab shell wastes
CN101411692A (en) Etoposide dispersible tablet and preparation method thereof
CN103142533B (en) Enteric coated tablet of etoposide
CN103006614B (en) Cefuroxime axetil capsule in non-gel state in water and preparation method of cefuroxime axetil capsule
CN101703238B (en) Sea-cucumber chitosan capsules and preparation method thereof
CN1198926A (en) Process for manufacturing hydropropyl cellulose powder with low substitution
CN1792366A (en) Ginkgo leaves dispersion tablets, and its preparing method
JP3310233B2 (en) Disintegrant for tablets
CN104027318A (en) Domperidone tablet and preparation method thereof
CN102988322B (en) Arginine ibuprofen tablet and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee